CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Expense ratio components for Dividend Aristocrats ETFs include management fees and other ongoing costs that reduce net returns.
20,481 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
AI hardware competition now hinges on storage alongside compute. NVIDIA drives data-center growth, while SanDisk ride...
Get a fresh, investor-focused look at hamilton (hg) 2025 earnings. We'll break down revenue engines, margins, and wha...
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...
Global energy markets reel from an unprecedented disruption in energy supply. CEOs grappling with greatest energy sho...
NVIDIA has etched itself as a premier growth stock by riding the AI wave and expanding its data-center and software e...
Bank of America's Vivek Arya sees Nvidia climbing to $350 as AI-driven demand sustains a broad, structural shift in c...
Investors are weighing SpaceX IPO buzz against a broader rotation into blue chips, with traders signaling a shift awa...
AI demand has sparked a rapid rally in memory stocks, but signs of inventory normalization and pricing pressure pose ...
The S&P 500 has delivered double-digit gains for years, but a new era may bring slower growth and higher costs. This ...
U.S. oil refiners are set for a historic profit surge as supply disruptions and stronger demand push refining margins...
The Pentagon and Energy Department completed the first airlift of a microreactor, moving a 5-MW unit from California ...